Compare Novo Nordisk A/S (NVO) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs SMX Security Matters plc — how do they compare? Novo Nordisk A/S trades at $44.9 (market cap $200.69B), while SMX Security Matters plc trades at $17.92 (market cap $19.09M). The key difference: Novo Nordisk A/S is far larger — about 10512.8× SMX Security Matters plc's market cap, and Novo Nordisk A/S pays a 3.98% dividend while SMX Security Matters plc pays none. Which is the better fit depends on your goals.
| NVO | SMX | |
|---|---|---|
Market Cap | $200.69B | $19.09M |
Sector | Health | Technology |
52-Week High | $63.98 | $74.08K |
52-Week Low | $35.29 | $12.87 |
Enterprise Value | $215.49B | -$12.23M |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
SMX trades at $17.88, down 8.21% on the day, with a bullish technical signal from moving averages and oscillators. The company reported a net loss of $169.18 million for 2025, with negative cash flow from operations but positive net cash flow due to financing. Recent news highlights expansion of its digital material passport platform for plastics and precious metals, targeting sustainability and supply chain verification markets.
The outlook hinges on commercialization success amid steep losses. Opportunities exist in regulatory tailwinds for recycled materials, but high cash burn and negative ROE pose significant risks. Investor sentiment is cautiously optimistic due to technology potential, yet profitability remains a distant milestone.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
